Hence, the enrichment of genomic alterations in high p53β tumours supports the associations between p53β and worse cancer outcomes; however, given that the majority of samples presented a novel sequence variant in CHEK2, further functional assays are needed to assess the impact of this variant on protein functions. This evidence concerns the gene CHEK2 and cancer.